GLP-1 FDA Warning Letters 2023–2026: Data Summary
Factual counts and distributions across all 162 official FDA warning letters concerning compounded, unapproved, or misbranded GLP-1 receptor agonists published on FDA.gov through late 2026.
Key findings from the dataset
- •Recent enforcement concentration: Letters from 2025 and 2026 account for 92.0% (149 of 162) of all GLP-1 warning letters in the dataset, with 78 letters issued in 2026 alone.
- •Semaglutide is the most frequently cited medication: Named in 146 of 162 letters (90.1%), followed by Tirzepatide in 111 letters (68.5%) and Retatrutide in 18 letters (11.1%).
- •Misbranding is the leading violation category: Cited in 153 of 162 letters (94.4%), followed by false or misleading marketing claims (117 letters, 72.2%) and unapproved new drug allegations (62 letters, 38.3%). (Note: Violation categories are assigned by TrimSoMo's classification rules (see methodology), not by FDA.)
- •Telehealth providers are the most common recipients: Telehealth entities received 110 of 162 letters (67.9%), followed by facilities/clinics (22 letters, 13.6%) and online pharmacies (13 letters, 8.0%).
Letters by Calendar Year
| Year | Letters | Share (%) |
|---|---|---|
| 2026 | 78 | 48.1% |
| 2025 | 71 | 43.8% |
| 2024 | 11 | 6.8% |
| 2023 | 2 | 1.2% |
| Total | 162 | 100.0% |
Letters by Medication Named
Letters citing multiple medications are counted in each category
| Medication | Letters | Involved in (%) |
|---|---|---|
| Semaglutide | 154 | 95.1% |
| Tirzepatide | 113 | 69.8% |
| Retatrutide | 23 | 14.2% |
| Liraglutide | 5 | 3.1% |
| Mazdutide | 4 | 2.5% |
| Cagrilintide | 3 | 1.9% |
| Survodutide | 2 | 1.2% |
| Lixisenatide | 1 | 0.6% |
Letters by Violation Category
Letters may cite multiple statutory violations
Note: Violation categories are assigned by TrimSoMo's classification rules (see methodology), not by FDA.
| Violation Category | Letters | Involved in (%) |
|---|---|---|
| Misbranding | 145 | 89.5% |
| False or misleading claims | 114 | 70.4% |
| Unapproved new drug | 66 | 40.7% |
| CGMP / insanitary conditions | 16 | 9.9% |
| Compounding outside 503A / 503B | 43 | 26.5% |
| Other regulatory violations | 39 | 24.1% |
Letters by Recipient Entity Type
| Entity Type | Letters | Share (%) |
|---|---|---|
| Telehealth | 110 | 67.9% |
| Other Facility | 22 | 13.6% |
| Online / Internet Pharmacy | 13 | 8.0% |
| Manufacturer / API | 8 | 4.9% |
| Compounding Pharmacy | 8 | 4.9% |
| Compounding pharmacy | 1 | 0.6% |
| Total | 162 | 100.0% |
How to cite this dataset
TrimSoMo GLP-1 FDA Warning Letter Dataset (2023–2026). Published by TrimSoMo. Available at: https://trimsomo.com/fda-warning-letters/report/. Data compiled from official U.S. FDA warning letters (FDA.gov).
License: Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). You are free to share and adapt this summary for non-commercial research, reporting, or academic purposes with appropriate attribution to TrimSoMo.